Kornimate/medical-research-clean huggingface dataset:
prospective study to assess des re-endothelization in bms restenosis and de-novo lesions

Conditions: Stable Coronary Artery Disease; Silent Myocardial Ischemia; In-stent(BMS)Restenosis; De-novo, Atherosclerotic, Coronary Lesions

Summary: the hypothesis of this study is that strut coverage occurs earlier when a des is implanted to treat a bms restenosis compared with atherosclerotic de-novo lesion. this hypothesis is supported by two different observations: first, when a des is implanted to treat a bms restenosis, stent struts are deployed and drugs are eluted on a soft tissue mostly characterized by extracellular matrix with a regular surface. in this case stent malposition is less likely to occur compared to atherosclerotic lesion whose surface is often more irregular and rich in calcium. second, patients who develop in-stent restenosis after bms implantation are likely to show a more pronounced neointima hyperplasia and, when a des is implanted to treat restenosis, reendothelialization is likely to occur earlier. if this hypothesis was verified, duration of dual antiplatelet therapy could be shortened after des implantation on bms restenosis with a clinical advantage in terms of bleeding risk. furthermore, a higher bleeding risk is often a reason for choosing a bms instead of a des; thus, patients presenting with bms restenosis are likely to have a higher bleeding risk and to benefit from a shorter period of dual antiplatelet therapy.


Eligibility criteria:
inclusion criteria: patients suitable for implantation of everolimus-eluting stents (xcience v, xience prime) because of stable/unstable angina or silent myocardial ischemia due to: * group a: single bms restenosis (\> 50% of luminal diameter) * group b: single de-novo lesion (\> 50% of luminal diameter) exclusion criteria: * contraindications to dual antiplatelet therapy * acute myocardial infarction within the previous 48 hours * significant left main coronary artery disease * reference vessel diameter \< 2.5 mm, * hemodynamic instability * chronic kidney disease with serum creatinine \> 2 mg/dl * pregnancy * allergy to contrast agent, everolimus, aspirin, clopidogrel * life expectancy \< 24 months * patients with possible low adherence to medical therapy
strengthening tourette treatment options using tms to improve cbit, a double-blind, randomized, controlled study

Conditions: Tourette Syndrome

Summary: this pilot study will investigate the clinical and neurophysiological effects of repetitive transcranial magnetic stimulation (rtms) followed by comprehensive behavioral intervention for tics (cbit) in adult patients with tourette's syndrome (ts). two groups of moderate disease severity will be randomized to receive active or sham rtms targeted to the supplementary motor area (sma) followed by eight cbit sessions. the change in tic frequency and severity (primary outcome) and neurophysiological changes (secondary outcome) will be compared between the two groups. the central hypothesis is that low frequency rtms will augment the effects of cbit through favorable priming of the sma network.


Eligibility criteria:
inclusion criteria: * age 18 years or older * diagnosis of tourette syndrome * moderate tic severity at baseline exclusion criteria: * presence of metallic objects or neurostimulators in the brain * pregnancy * history of active seizures or epilepsy * contraindications to receiving fmri * inability to participate in cbit due to other underlying cognitive or medical condition

Keywords: tourette syndrome comprehensive behavioral intervention for tics transcranial magnetic stimulation
assessing the health impact of a combined water and sanitation intervention in rural odisha, india

Conditions: Diarrhea; Enteric Infection; Soil-transmitted Helminth Infection; Stunting

Summary: this is a matched-cohort study designed to assess the health impact of a rural demand-driven water and sanitation intervention that provides piped treated water and household level pour-flush latrines and bathing rooms, as implemented by gram vikas.

we will undertake a matched-cohort study among 84 villages in ganjam district, orissa, india to assess the health impact of a program that provides improved water supplies and sanitation to rural villages.

Eligibility criteria:
inclusion criteria: * households in participating villages will be eligible to participate in the study if they have at least one child under 5 years. exclusion criteria: * none
the predictors of the neonatal hyperbilirubinemia

Conditions: Hyperbilirubinemia, Neonatal

Summary: the oxygen tension increases more than 3 times from fetus to neonate. the oxidant stress happens. and it will cause the destruction of rbc. so, we propose that the ros may play an important role of neonatal hyperbilirubinemia. there is strong association between the bilirubin level and ros levels at 3 days old in our pilot study.

the incidence of neonatal jaundice is higher in eastern population than western people. the bilirubin comes from the destruction of rbc which heme is released and catabolized. if the bilirubin enters into the brain and deposits in basal ganglion, it will cause apoptosis of the neuronal cells, that is so called kernictrus, which is the major complication of the neonatal jaundice. however, the bilirubin has its own antioxidant protective effect. many clinical or basic studies tried to find out the relationship of bilirubin and reactive oxygen species (ros) in recent years. the american association of pediatrics proposed the management principle of neonatal jaundice in 1994. it postponed the management criteria of neonatal jaundice besides, early discharge (before 48 hour-old) was the trend in many countries. it may be dangerous because the neonatal jaundice appears after 48 hour-old. whether the criteria and the trend will cause the elevation of the incidence of kernictrus, is always the major concern of clinicians. so, searching factors to predict neonatal hyperbilirubinemia causes the interest of many investigators. the predictors are divided into risk-factor based and normogram based. but they are still not suitable for all populations.

Eligibility criteria:
inclusion criteria: * health neonate exclusion criteria: * perinatal insults prematurity

Keywords: hyperbilirubinemia free radicals health neonate
treatment of patients with traumatic or iatrogenic vessel injuries

Conditions: Iatrogenic Vessel Injury

Summary: the purpose of this study is to confirm device efficacy and safety of the gore® viabahn® endoprosthesis (hereafter "vb device") for the treatment of traumatic or iatrogenic vessel injury in thoracic, abdominal, and pelvic arteries (except the aorta, coronary, brachiocephalic, carotid, vertebral and pulmonary arteries).


Eligibility criteria:
patients with traumatic or iatrogenic vessel injuries in thoracic, abdominal, and pelvic arteries (except the aorta, coronary, brachiocephalic, carotid, vertebral and pulmonary arteries ) with a reference vessel diameter ranging from 4.0 to 12.0mm.
emotional and cognitive abilites of schizophrenia patients at various time points

Conditions: Schizophrenia

Summary: longitudinal investigation of cognitive, emotional and illness awareness of schizophrenia outpatients (shalvata mental health center). the study uses computerized assessment of cognitive functioning and questionnaire to assess performance of patients assessed in the past as part of a routine clinical assessment.


Eligibility criteria:
inclusion criteria: 1. schizophrenia diagnosis by a senior psychiatrist (according to dsm-4 criteria). 2. age between 18-65 (male and female). 3. prior cognitive assessment in the emotional-cognitive research laboratory (shalvata mental health center) 4. signed informed consent by participants. exclusion criteria: 1. hospitalization at the time of experiment. 2. a history of brain-injury or other neurological condition precluding participation in the study. 3. guardianship. 4. current alcohol or drug abuse

Keywords: cognition, attention, memory, executive functions, illness-awareness, insight.
clinical study on adoptive treatment of mdr-tb with allogeneic γδt cells

Conditions: Multi-drug Resistant Tuberculosis

Summary: brief summary: allogeneic γδt cells from healthy donor will be administrated intravenously to patients with the mdr-tb，and then the safety and efficacy of γδt cells will be evaluated.

all patients with multi-drug resistant pulmonary tuberculosis will be assigned into 2 groups(study group and control group)，both groups will receive conventional treatment. allogeneic γδt cell will be administrated intravenously to patients in the study group (but not the control group) every two weeks for 6 months

Eligibility criteria:
inclusion criteria: 1. aged 18-50 years old, male or female; 2. informed consent; 3. patients with multidrug-resistant tuberculosis diagnosed by positive sputum smear and tubercle bacillus culture. exclusion criteria: 1. aids, hepatitis b and other viruses, bacterial infections; 2. patients with other diseases such as diabetes, cancer, hypertension, coronary heart disease, endocrine system diseases, mental diseases, neurological diseases, and vascular circulatory diseases; 3. others after being evaluated by clinicians participating in this project, it is not suitable to participate in immune cell therapy; 4. those who do not agree to be included.

Keywords: mdr-tb allogeneic γδt cells adoptive treatment
a prospective, observational, drug utilization study of subjects taking truvada for pre-exposure prophylaxis in the usa

Conditions: Pre-exposure Prophylaxis for Prevention of HIV Infection

Summary: this is a prospective, 3-year observational study to describe drug utilization in uninfected individuals (uis) who initiate emtricitabine (ftc)/tenofovir disoproxil fumarate (tdf) (truvada®) for a pre-exposure prophylaxis (prep) indication. an electronic source of pharmacy/medical encounter information will be used to assess the demographics and other characteristics of the subjects prescribed ftc/tdf or its components in a prospective fashion. the data provider will supply all the de-identified information regarding each visit/interaction that the subject has had with the health system and all the diagnoses and medications that the ui has had prospectively and retrospectively for the length of time captured by the source selected. 200 physicians who prescribe ftc/tdf for a prep indication will be sampled from the same source.


Eligibility criteria:
key inclusion criteria: * patient/ uninfected individual * adult (any sex/gender, including transgender) ≥18 years old * taking ftc/tdf prescribed for any indication or its components prescriber * possesses an active health care professional license in good standing, with the authority to prescribe prescription medications, either independently (eg, physician) or under legally permissible arrangements for prescribing under physician supervision (eg, nurse practitioner or physician assistant) * practice site is within the usa * having prescribed ftc/tdf for a prep indication key exclusion criteria: * there are no exclusion criteria for individuals or prescribers note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: ftc/tdf prep truvada drug utilization
prevalence and determinants of anemia during the third trimester of pregnancy

Conditions: Anemia of Pregnancy

Summary: this cross-sectional study was conducted on 383 pregnant women who attended the antenatal care clinic during their third trimester at beni-suef university hospital. a proper history was taken from each participant. all women were subjected to routine antenatal care, including physical examinations, ultrasound examinations, and routine laboratory tests. according to who criteria, anemia was diagnosed with a hemoglobin level of less than 11.0 g/dl. anemia was further divided into three degrees; mild with hemoglobin level 10-10.9 g/dl, moderate with hemoglobin level 7-9.9 g/dl, and severe with hemoglobin level \< 7.0 g/dl.

this cross-sectional study was conducted on 383 pregnant women who attended the antenatal care clinic during their third trimester at beni-suef university hospital. a proper history was taken from each participant regarding age, educational level, residency (urban or rural), occupation, family income, frequency of antenatal visits, obstetric history, medical history, and surgical history. nutritional history is taken to detect the frequency intake of meat/month, chicken/week, fish/week, fruits/week, vegetables/week, and tea/day. history of iron supplements intake was taken. all women were subjected to routine antenatal care, including a physical examination (e.g., measuring blood pressure), ultrasound, and umbilical artery doppler examination. a blood sample was taken from each enrolled woman for standard laboratory tests such as complete blood picture, blood group, rh type, and blood sugar test if there is a risk. a urine sample was taken for urine analysis. blood from each participant was drawn from the cubital vein into appropriate blood collection tubes using vacuum tube needles (becton dickinson medical devices co. ltd., franklin lakes, usa). k2edta tubes were used for cbc. samples were transported and tested within 4 hours after collection. measured cbc parameters included rbc, hgb, hct, mean corpuscular volume (mcv), mean corpuscular hemoglobin (mch), mch concentration (mchc), platelet count (plt), wbc, and wbc differentials, including percentages and absolute counts of neutrophils (neut% and neut), lymphocytes (lym% and lym), monocytes (mono% and mono), basophils (baso% and baso), and eosinophils (eo% and eo). according to who criteria, anemia was diagnosed with a hemoglobin level of less than 11.0 g/dl. anemia was further divided into three degrees; mild with hemoglobin level 10-10.9 g/dl, moderate with hemoglobin level 7-9.9 g/dl, and severe with hemoglobin level \< 7.0 g/dl.

Eligibility criteria:
inclusion criteria: * pregnant women during their third trimester exclusion criteria: * women with chronic medical illness

Keywords: anemia hemoglobin third trimester pregnancy outcome
a comparison of different fecal occult blood test for colorectal cancer screening

Conditions: Colorectal Cancer

Summary: colorectal cancer is a leading cause of cancer-related morbidity and mortality. crc-related death can be prevented through fecal occult blood test screening. because of economic and high sensitivity, fecal immunochemical test is recommended for screening population of crc. the purpose of this study is to compare the accuracy of 4 different fecal occult blood testing in medium and high risk screening population in chinese.

colorectal cancer (crc) is one of the most common cancer worldwide, and cause a huge number of cancer-associated mortality. crc screening has been shown to be effective in reducing the incidence of, and mortality from, crc. there are several recommended screening options for screening population of crc, including colonoscopy and fecal occult blood testing (fobt) .colonoscopy has higher sensitivity and specificity than fobt for detecting advanced colorectal neoplasia but also has several disadvantages, including higher cost and poorer compliance. therefore, many patients prefer fobt to colonoscopy. fobt includes guaiac-based fecal occult blood test (gfobt) and fecal immunochemical test (fit). fit includes quantitative fit (qfit) and qualitative fit. qfit can provide a value of concentration of hemoglobin in stool and are increasingly recommended for crc. in china, the most common use fobt is qualitative fit and the comparison of quantitative and qualitative fit is lack in screening population of crc in chinese. to add to the evidence on fit performance characteristics for detection of crc, the investigators design this research to compare qfit with other 3 qualitative fobt（two of them are colloidal gold qualitative fits and one of them is chemical and immunologic combined detection）in medium and high risk screening population.

Eligibility criteria:
inclusion criteria: * adults 50-75 years old; * asia-pacific colorectal screening score(apcs): medium or high risk. exclusion criteria: * apcs score: low risk; * people with history of intestinal surgery; * people with history of crc; * people with history of inflammatory bowel disease, ischemic enteritis, vascular malformation of intestine or other disease resulting in intestinal tract bleeding; * people with symptoms including visible rectal bleeding, hematuria, severe and acute diarrhea and bristol feces score 7th type; * pregnancy, lactation or menstrual phase; * severe congestive heart failure or other sever disease cause cannot tolerate colonoscopy.

Keywords: colorectal cancer fecal occult blood testing quantitative fecal immunochemical test
middle school success over stress

Conditions: Parenting; Parent-Child Relations; Depression; Self-regulation

Summary: it is clear that the covid-19 pandemic has impacted families adversely in multiple ways, including economic stressors, mental health-related functioning, social/familial functioning, as well as responses to mandated safety measures (e.g. social distancing, stay-at-home orders, mask-wearing). furthermore, families of school-age children have had to navigate online instruction and home schooling in the context of these difficult circumstances with little preparation for doing so effectively. school districts have varied widely in their ability to support parents during this crisis. these stressors are likely to have disproportionately adverse effects on lower-income and racial/ ethnic minority populations, for whom economic, academic, and family-level challenges were already pronounced. for instance, health effects of covid-19 have hit african american and latinx populations with disproportionate severity, including higher rates of hospitalization and death. given the scale of pandemic impacts for families with school-aged children, the identification of effective family-focused interventions that target core mechanisms of change with a broad range of benefits for parents and youth across diverse populations, and that can be brought to scale rapidly and with fidelity, represent critical public health goals. in this research study the investigators will adapt and test the efficacy of the family check-up online as a treatment to foster resilient family functioning in response to the covid-19 pandemic. the investigators will test the effects of the adapted fcu online program on key mechanisms of change that are predicted to directly impact child and family functioning: parenting skills, parental depression, and parent and child self-regulation. the investigators predict that changes in these key targets of the intervention will impact participant's response to the covid-19 pandemic, including youth depression and behavior problems, the ability to cope with pandemic-focused stressors, and social/familial functioning.


Eligibility criteria:
inclusion criteria: * a caregiver must have a child between the ages of 10 and 14; * the caregiver must be the parent or legal guardian of the participating youth; * the caregiver must have a smartphone with text messaging capability and access to email; and * the caregiver must score at least 1 or above on the patient health questionnaire-2, or score at least 2 on any item of the perceived stress scale-4. exclusion criteria: * the caregiver is unable to read in either english or spanish; * the child is unable to complete the survey without parent's help; or * the family is already participating in another study of the university of oregon's prevention science institute.
steroids in covid-19 study

Conditions: Coronavirus Infection

Summary: at the time of writing (3/4/2020), close to a million people have been infected by the sars-cov-2 coronavirus around the world. the severe clinical condition that leads to deaths is now called covid-19. currently, there are no effective treatments for the early or late stages of this illness. governments worldwide have undertaken dramatic interventions to try and reduce the rate of spread of this deadly coronavirus. early data from multiple studies in china, where the virus originated, show that severe cases of covid-19 are not as prevalent in patients with chronic lung diseases as expected. this data has been confirmed by the italian physicians. the investigators think that the widespread use of inhaled corticosteroids reduces the risk of covid-19 pneumonia in patients with chronic lung disease. early microbiological data also shows that these corticosteroids are effective at slowing down the rate of coronavirus replication on lung cells. inhaled corticosteroids are widely used to manage common lung conditions, such as asthma. this type of medicine is among the top 3 most common medication prescribed around the world. their safety is well understood, and their potential side effects are mild and reversible. the investigators propose to test this idea that, in participants early in the course of covid-19 illness, daily high dose inhaled corticosteroids for 28 days, will reduce the chances of severe respiratory illness needing hospitalisation. we will also study the effect of this inhaled therapy on symptoms and viral load.


Eligibility criteria:
inclusion criteria: * participant is willing and able to give informed consent for participation in the trial * male or female, aged 18 years or above * new onset of symptoms suggestive of covid-19 e.g. new onset cough and/or fever, and/or loss of smell or taste within 7 or fewer days of participant being seen at visit 1 * in the investigator's opinion, is able and willing to comply with all trial requirements exclusion criteria: * a known allergy to investigational medicine product (imp) (budesonide) * any known contraindication to any of the imps (budesonide) * patient currently prescribed inhaled or systemic corticosteroids * recent use, within the previous 7 days of inhaled or systemic corticosteroids * patient needs hospitalisation at time of study consent * any other significant disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial. * participants who have participated in another research trial involving an investigational product in the past 12 weeks.

Keywords: covid-19 coronavirus infection sars-cov-2